MTHFD2-mediated redox homeostasis promotes gastric cancer progression under hypoxic conditions

Hai-Yu Mo,Ruo-Bing Wang,Meng-Yao Ma,Yi Zhang,Xin-Yu Li,Wang-Rong Wen,Yi Han,Tian Tian

DOI: https://doi.org/10.1080/13510002.2024.2345455

2024-05-10

Redox Report

Abstract:Objectives: Cancer cells undergo metabolic reprogramming to adapt to high oxidative stress, but little is known about how metabolic remodeling enables gastric cancer cells to survive stress associated with aberrant reactive oxygen species (ROS) production. Here, we aimed to identify the key metabolic enzymes that protect gastric cancer (GC) cells from oxidative stress.

biochemistry & molecular biology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is how gastric cancer cells maintain redox balance through the over - expression of specific metabolic enzymes under hypoxic conditions, thereby promoting tumor progression. Specifically, the study focuses on the role of methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) in this process. The paper verifies through a series of experiments that MTHFD2 is over - expressed in gastric cancer cells and is associated with poor prognosis in patients. Further research shows that MTHFD2 helps cells resist oxidative stress caused by hypoxia by maintaining intracellular NADPH levels, thereby promoting the development of gastric cancer. In addition, the paper also explores the potential therapeutic value of inhibiting MTHFD2. Whether through gene knockout or drug inhibition, it can effectively reduce the growth and survival of gastric cancer cells, especially in a hypoxic environment.

### Main research contents and findings:
1. **The poor relationship between high expression of MTHFD2 and the prognosis of gastric cancer patients**:
- The study found that MTHFD2 is significantly over - expressed in gastric cancer tissues, and this over - expression is related to the decrease in patient survival rate.
- Through Kaplan - Meier analysis, the overall survival rate and disease - free survival rate of patients with high MTHFD2 expression are significantly lower than those of patients with low expression.

2. **The impact of MTHFD2 on the proliferation of gastric cancer cells**:
- Researchers observed a significant decrease in the proliferation ability of gastric cancer cells and a weakened ability to form clones by knocking down MTHFD2 gene.
- These results indicate that MTHFD2 plays a crucial role in the proliferation of gastric cancer cells.

3. **The role of MTHFD2 under hypoxic conditions**:
- The study found that under hypoxic conditions, MTHFD2 is crucial for maintaining intracellular NADPH and GSH levels. These molecules help to clear intracellular reactive oxygen species (ROS), thereby protecting cells from oxidative stress damage.
- Knockdown of MTHFD2 leads to a decrease in the intracellular NADPH/NADP+ and GSH/GSSG ratios, an increase in ROS levels, and ultimately an increase in cell death.

4. **The anti - tumor effect of MTHFD2 inhibitor DS18561882**:
- Researchers used an MTHFD2 inhibitor DS18561882 and found that this drug can significantly reduce the NADPH level in gastric cancer cells, increase the ROS level, and induce cell death.
- In in - vivo experiments, DS18561882 significantly inhibits the growth of gastric cancer cells, reduces the volume and weight of tumors, and no obvious toxic reactions were observed.

### Conclusion:
This study reveals an important mechanism by which MTHFD2 promotes tumor progression by maintaining redox balance in gastric cancer cells. The study not only provides a new perspective for understanding the biological characteristics of gastric cancer but also provides a theoretical basis for the development of treatment strategies targeting MTHFD2. In particular, the MTHFD2 inhibitor DS18561882 shows good anti - tumor effects in both in - vitro and in - vivo experiments and has potential clinical application prospects.